Key Drivers
- Persistent Losses
- Liquidity Decline
- Negative Cashflow
AIAI Summary
TWST's upside now hinges on converting the Lilly TuneLab validation and 49% therapeutics growth into recurring, high-margin AI data-services revenue and reaching FY2026 Q4 adjusted EBITDA breakeven; with the stock already priced for this outcome, investors should require proof of cash-flow improvement and limited further dilution before adding exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Persistent Losses
- •Liquidity Decline
- •Negative Cashflow
TWST's improved gross margin is offset by persistent losses, weakening liquidity and cash flow, and an elevated valuation, suggesting caution despite adequate balance-sheet flexibility.
Price Behavior
Key Price Behavior Insights:
- •Strong breakout
- •Overbought momentum
- •Key support
TWST surged 22.5% over the last month to a new high, but RSI near 70 signals pullback risk; bullish momentum holds above $155–156, while a break below $143–145 would weaken the trend.
Sharp acceleration in gains from
Sentiment & News
Key News Insights:
- •Eli Lilly deal
- •Raised revenue guidance
- •Profitability gap
Twist Biosciences gains AI drug-discovery momentum and institutional backing, but its high valuation still hinges on achieving profitability.
The Eli Lilly collaboration strengthens Twist's strategic growth narrative, though sustained upside depends on converting revenue growth into profits
Similar Companies in Healthcare
Other companies in the same sector with AI ratings